We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
-14.02%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$270M
AUM Growth
+$46.4M
Cap. Flow
+$86.8M
Cap. Flow %
32.16%
Top 10 Hldgs %
7.48%
Holding
501
New
128
Increased
202
Reduced
102
Closed
67

Sector Composition

Rank Sector Weight
1 Real Estate 18.55%
2 Healthcare 17.07%
3 Materials 11.98%
4 Financials 11.43%
5 Energy 8.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CUE icon
451
Cue Biopharma
CUE
$137M
-476
Closed -$70K
CVM icon
452
CEL-SCI Corp
CVM
$20.6M
-654
Closed -$77K
DTIL icon
453
Precision BioSciences
DTIL
$187M
-632
Closed -$58K
EPIX
454
DELISTED
ESSA Pharma
EPIX
-12,885
Closed -$80K
FDMT icon
455
4D Molecular Therapeutics
FDMT
$543M
-7,683
Closed -$116K
FULC icon
456
Fulcrum Therapeutics
FULC
$249M
-9,496
Closed -$225K
KALV
457
DELISTED
KalVista Pharmaceuticals
KALV
-11,784
Closed -$174K
KRON
458
DELISTED
Kronos Bio
KRON
-11,844
Closed -$86K
LXRX icon
459
Lexicon Pharmaceuticals
LXRX
$991M
-39,262
Closed -$82K
LITS
460
Lite Strategy Inc
LITS
$33.2M
-3,231
Closed -$39K
MGNX icon
461
MacroGenics
MGNX
$254M
-9,556
Closed -$84K
OLMA icon
462
Olema Pharmaceuticals
OLMA
$1.05B
-17,135
Closed -$73K
ORIC icon
463
Oric Pharmaceuticals
ORIC
$1.24B
-12,914
Closed -$69K
PASG icon
464
Passage Bio
PASG
$14.8M
-1,166
Closed -$72K
PLRX icon
465
Pliant Therapeutics
PLRX
$66.9M
-10,224
Closed -$72K
PRAX icon
466
Praxis Precision Medicines
PRAX
$8.8B
-568
Closed -$87K
QNCX icon
467
Quince Therapeutics
QNCX
$17.5M
-68
Closed -$85K
RNAC icon
468
Cartesian Therapeutics
RNAC
$229M
-1,641
Closed -$61K
RYTM icon
469
Rhythm Pharmaceuticals
RYTM
$7.28B
-16,317
Closed -$188K
SRRK icon
470
Scholar Rock
SRRK
$5.86B
-6,212
Closed -$80K
STRO icon
471
Sutro Biopharma
STRO
$398M
-1,067
Closed -$88K
STTK icon
472
Shattuck Labs
STTK
$672M
-18,546
Closed -$79K
TCRT icon
473
Alaunos Therapeutics
TCRT
$4.71M
-876
Closed -$86K
TSHA icon
474
Taysha Gene Therapies
TSHA
$1.59B
-10,878
Closed -$71K
TSVT
475
DELISTED
2seventy bio
TSVT
-13,134
Closed -$224K

Similar funds

Virtus ETF Advisers's Q2 2022 Portfolio in Review

As of Q2 2022, Virtus ETF Advisers held 501 positions worth $270M, up 21% from $223M the previous quarter. Its ten largest holdings account for 7.5% of the portfolio.

Virtus ETF Advisers deployed $86.8M of net new capital in Q2 2022, opening 128 new positions and adding to 202 existing holdings. Its largest new stake was ConocoPhillips: 7,627 shares worth $685K.

By sector, the portfolio is most concentrated in Real Estate at 19% of assets, down from 20% a quarter earlier, followed by Healthcare and Materials.

On the sell side, the largest reduction was Agnico Eagle Mines, an estimated $1.83M trimmed.

  • Virtus ETF Advisers's largest Q2 2022 buy was ConocoPhillips: 7,627 shares worth $685K.
  • Virtus ETF Advisers added most to Realty Income in Q2 2022, an estimated $931K increase.
  • Virtus ETF Advisers's biggest Q2 2022 reduction was Agnico Eagle Mines, cutting an estimated $1.83M.
  • Virtus ETF Advisers fully exited BP Midstream Partners LP Common Units representing Limited Partner Interests in Q2 2022, selling an estimated $1.76M.
  • Virtus ETF Advisers's ten largest holdings make up 7.5% of its $270M portfolio in Q2 2022.
  • Virtus ETF Advisers opened 128 new positions and closed 67 in Q2 2022.
  • Virtus ETF Advisers's portfolio value rose 21% quarter-over-quarter to $270M.

Based on Virtus ETF Advisers's 13F filing for Q2 2022, filed 12 Aug 2022.